Cervical adenosquamous carcinoma

This phase III trial tests whether giving an extra round of chemotherapy and immunotherapy (pembrolizumab) before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the cancer growing. About 336 participants will be rando…

This trial is investigating whether adding radiation therapy to a standard combination of chemotherapy and two targeted drugs can improve outcomes for people with stage IVB cervical cancer. The study combines external beam radiation and internal brachytherapy with cisplatin, pacl…

This study looks at whether surgically removing para-aortic lymph nodes before standard chemoradiation can improve disease-free survival in people with stage IIIC1 cervical cancer. About 510 participants will be randomly assigned to either standard treatment or surgery plus tailo…

This early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…

This study compares a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) to the standard longer course for women with locally advanced cervical cancer in Uganda. About 278 participants will receive either the shorter or standard radiation, plus chemotherapy a…

This study tests a modified virus (KD01) that targets and kills cancer cells, given alone or with an immunotherapy drug (AK104). It includes 97 women with cervical or endometrial cancer, some of whom have not responded to standard treatments. The goal is to see if the virus is sa…

This study tests whether adding the drug serplulimab to standard chemoradiotherapy after surgery can help prevent cervical cancer from returning in patients with multiple risk factors. About 134 women aged 18-65 with PD-L1 positive cervical cancer will be randomly assigned to rec…